Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) Inhibitors in Type 2 Diabetes Mellitus

Cardiovascular (CV) diseases are the leading cause of mortality and morbidity in patients with type 2 diabetes mellitus (DM). Therefore, there has been an increasing endorsement from diabetic associations across the globe for the use of anti-diabetic drugs, which not only provide not only glycemic c...

Descripción completa

Detalles Bibliográficos
Autores principales: Rehman, Saad U, Rahman, Faiqa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419148/
https://www.ncbi.nlm.nih.gov/pubmed/32802621
http://dx.doi.org/10.7759/cureus.9655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419148/
https://www.ncbi.nlm.nih.gov/pubmed/32802621
http://dx.doi.org/10.7759/cureus.9655

Ejemplares similares